The traditional pharmaceutical industry business model has come under extraordinary pressure in recent years. Many agree it will be challenged both economically and operationally to act quickly enough to produce the types of innovative treatments demanded by global markets. Major scientific and technological advances, along with increasing global demand for medicines will help drive much of pharma's fortune into the next decade and beyond. But if the industry is to prosper, companies will need to embrace and pursue a different path.
Many of the conditions that will determine what happens in 2020 are already in place. Most of the products to be launched are already in the pipeline; development processes are similar to those used over the past 10 years; a demanding commercial environment looks set to continue; and the prevailing management culture remains that of the late twentieth century. A more flexible and adaptive model must be adopted.
PwC’s newest report Pharma 2020: From vision to decision discusses the challenges facing the industry at this critical juncture in time and what companies must do to succeed over the next decade and beyond.
Global Pharmaceuticals and Life Sciences Industry Leader
Global Pharmaceuticals and Life Sciences Advisory Services Leader
US Pharmaceuticals and Life Sciences Advisory Services Leader
CPE credit will not be offered for this webcast.